Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of OPC-6535 in patients with active Crohn's disease
jRCT2080220213Phase 2Terminated
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tetomilast in Crohn's disease, sponsored by Otsuka Pharmaceutical Co., Ltd. Started Mar 2006; status: terminated.
02
Drugs
tetomilast
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2080220213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220213.